Psyence Group Announces Cantheon Capital Private Placement
Summary
The Psyence Biomed Division works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Informed by nature and guided by science, we built and operate one of the worlds first federally licensed commercial psilocybin mushroom cultivation and production facilities in Southern Africa. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. These forward-looking statements are based on a number of assumptions, including the assumptions that Psyence will obtain all such regulatory and other approvals as may be required to pursue its clinical trials on the drug product referred to in the news release, the results of such clinical trials will be positive, Psyence will be eligibility to receive the benefits flowing from the Australian Federal Governments Research & Development tax incentive program and that Cantheon will make payment of the first tranche of investment by the date quoted in the news release. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice.